GO
Loading...

Why investors should be exposed to biotech

Monday, 31 Mar 2014 | 5:30 AM ET

Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.